Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...

The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...

The first ‘real-world study’ into the weight loss drug, Mounjaro, has now started in Greater Manchester. Thousands of ...